Pay in 4 interest-free payments of $5.34 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Long term persistence is what will be interesting to observe
This action marks the drug as the first-ever generic glucagon-like peptide-1 (GLP-1) receptor agonist indicated for adults with obesity or overweight who also have a weight-related medical problem and pediatric patients aged 12 to 17 years with a weight greater than 60 kg and obesity specifically to aid weight loss and keep the weight off
GLP-1 agonist medications mimic this hormones effects to help your body produce more insulin, slow digestion, and promote satiety
Antioxidant Support : Protects cells from damage caused by free radicals
,aspect=ignore)
Oral Diseases, 30 (8), 51605174
Obesity segment accounted for USD 10.52 Billion in 2025, representing 28% share of the GLP-1 Drug Market, and is expected to grow at a CAGR of 29.4% driven by increasing obesity prevalence and rising awareness of weight management therapies
US$ 28.16
US$ 21.85
US$ 26.78
US$ 25.95
